Mercier Johanna, Chief Commercial Officer at Gilead Sciences (GILD), has demonstrated a consistent pattern of selling activity in the company’s stock over the past year, with no recent purchases. Since August 2025, Johanna has executed 12 sales totaling approximately $24.2 million, dwarfing their total buy value of $4.17 million across all historical transactions. The most significant disposals occurred on February 17, 2026, when Johanna sold shares worth $1.46 million and $2.84 million, alongside an option exercise (code M) valued at $1.67 million. Another notable transaction took place on February 3, 2026, with a $3.55 million sale following the vesting of restricted stock (code F). Smaller but recurring sales, such as $354,240 on October 15, 2025, and $340,710 on September 15, 2025, suggest a methodical approach to reducing holdings.
The transactions reveal a clear divestment trend, with Johanna’s most recent activity including a $432,690 sale on March 16, 2026, and a $477,768 vesting-related sale on March 10, 2026. While some filings reflect administrative events like awards (code A) with no immediate monetary value, the overwhelming majority represent outright sales. Johanna’s trading history is concentrated solely in GILD, with no activity in other securities. The absence of buys during this period, combined with the scale and frequency of disposals, indicates a sustained reduction in exposure to Gilead Sciences stock.
AI-assisted summary